Cabaletta Bio Inc.

10.70-0.0500-0.47%Vol 68.99K1Y Perf 59.94%
Apr 16th, 2021 16:00 DELAYED
BID10.70 ASK10.73
Open10.75 Previous Close10.75
Pre-Market- After-Market-
 - -  - -%
Target Price
21.00 
Analyst Rating
Strong Buy 1.17
Potential %
96.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap257.47M 
Earnings Rating
Price Range Ratio 52W %
44.48 
Earnings Date
11th May 2021

Today's Price Range

10.0610.78

52W Range

6.1516.38

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.56%
1 Month
-10.68%
3 Months
-17.94%
6 Months
-11.93%
1 Year
59.94%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CABA10.70-0.0500-0.47
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.34-0.40-17.65
Q03 2020-0.47-0.3623.40
Q02 2020-0.45-0.3522.22
Q01 2020--0.33-
Q04 2019-0.83-0.3360.24
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th May 2021
Estimated EPS Next Report-0.49
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume68.99K
Shares Outstanding24.06M
Trades Count1.15K
Dollar Volume1.55M
Avg. Volume106.95K
Avg. Weekly Volume64.67K
Avg. Monthly Volume98.52K
Avg. Quarterly Volume103.72K

Cabaletta Bio Inc. (NASDAQ: CABA) stock closed at 10.7 per share at the end of the most recent trading day (a -0.47% change compared to the prior day closing price) with a volume of 69.38K shares and market capitalization of 257.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Cabaletta Bio Inc. CEO is Steven Nichtberger.

The one-year performance of Cabaletta Bio Inc. stock is 59.94%, while year-to-date (YTD) performance is -14.26%. CABA stock has a five-year performance of %. Its 52-week range is between 6.15 and 16.38, which gives CABA stock a 52-week price range ratio of 44.48%

Cabaletta Bio Inc. currently has a PE ratio of -7.80, a price-to-book (PB) ratio of 2.38, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.03%, a ROC of -66.42% and a ROE of -26.90%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cabaletta Bio Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Cabaletta Bio Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Cabaletta Bio Inc. is Strong Buy (1.17), with a target price of $21, which is +96.26% compared to the current price. The earnings rating for Cabaletta Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cabaletta Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cabaletta Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.41, ATR14 : 0.90, CCI20 : -103.36, Chaikin Money Flow : 0.12, MACD : -0.41, Money Flow Index : 68.71, ROC : 1.61, RSI : 50.91, STOCH (14,3) : 32.99, STOCH RSI : 0.53, UO : 47.68, Williams %R : -67.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cabaletta Bio Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.17
Strong Buy
1.17
Strong Buy
1.17

Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its technology uses chimeric autoantibody receptor T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies while sparing normal B cells. The firm offers preclinical development for the treatment of muscle-specific kinase myasthenia gravis, mucocutaneous PV, and Hemophilia A with factor VIII, or FVIII, alloantibodies. Its products comprise of DSG3/1-CAART, MuSK-CAART, and FVIII-CAART. The firm's initial focus is on Pemphigus Vulgaris, which is an autoimmune blistering skin disease.

CEO: Steven Nichtberger

Telephone: +1 267 759-3100

Address: 2929 Arch Street, Philadelphia 19104, PA, US

Number of employees: 31

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

54%46%

News

Stocktwits